Evidence map›Paper›PMID 28061985›Full record

ReviewSeminars in oncology2016

Multiple myeloma epidemiology and survival: A unique malignancy.

Dickran Kazandjian

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Seminars in oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05874193 (A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma), which is not on this map. Cited by 413 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
413citing papers in PubMed, 6 pooled it
12.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05874193 phase2not yet recruitingnot on this mapstarted 2026, after this paper: background citation

A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma

TypeinterventionalSponsorCristiana Costa Chase, DORan2026 to 2028Enrolled33ConditionsRelapsed/Refractory Multiple MyelomaArmsBelantamab mafodotin
3 · Its place in the literature

Who cites it

413 citing papers in PubMed, 6 syntheses or guidelines pooled it, 759 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Article
  9. Article
  10. Observational
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

353 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Dickran KazandjianMyeloma Program, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD. Electronic address: kazandjiandg@mail.nih.gov.
Center for Cancer Research · US

Funding

Intramural NIH HHS Z99 CA999999
6 · The paper itself

Abstract

Multiple myeloma (MM), although a rare disease, is the second most common hematologic malignancy. It is found in the spectrum of plasma cell dyscrasias, which begins with monoclonal gammopathy of unknown significance (MGUS) to overt plasma cell leukemia and extramedullary myeloma. MM is associated with significant morbidity due to its end-organ destruction. It is a disease of the older population and its incidence in the African American population is twice that of the European American population. Improvements in the treatment of MM in the past couple of decades, beginning with the use of autologous stem cell transplantation followed by availability of novel treatments such as immunomodulatory drugs (ImIDs) and proteasome inhibitors (PIs) has transformed the natural history of the disease leading to longer survival times. Advancements in the diagnosis, monitoring, and treatment of MM are of the utmost importance as the general population lives longer due to other improvements in health care. The recent introduction of novel therapies has been paralleled by advancements in the monitoring of MM, namely, by the availability exquisitely sensitive techniques in detecting minimal residual disease. As drug development and technology continues to improve, it will be important to design rationale clinical trials enrolling patient populations that represent the overall population, including racial minorities and the elderly, so that trial results can be appropriately extrapolated. Herein, the changing epidemiology, improvements in survival, and the health disparity observed in important subgroups of MM are reviewed.

Indexed as

AdultAgedAged, 80 and overHumansMiddle AgedMultiple MyelomaTime FactorsEpidemiologyHealth disparityMGUSMultiple myelomaSmoldering myeloma

Identifiers

PMID28061985
PMCPMC5283695
OpenAlexW2549396793

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.